Stockscreener 앱 받기
4.00
0.50%
0.02
전일 마감가:
$3.98
열려 있는:
$4
하루 거래량:
176.13K
Relative Volume:
1.37
시가총액:
$54.69M
수익:
-
순이익/손실:
$-59.52M
주가수익비율:
-0.9081
EPS:
-4.4049
순현금흐름:
$-51.87M
1주 성능:
-0.25%
1개월 성능:
+47.60%
6개월 성능:
+57.48%
1년 성능:
-16.32%
1일 변동 폭
$3.60
$4.10
1주일 범위
$3.60
$4.75
52주 변동 폭
$1.70
$4.90
Onkure Therapeutics Inc Stock (OKUR) Company Profile
명칭
Onkure Therapeutics Inc
전화
(720) 307-2892
주소
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.00 | 54.69M | 0 | -59.52M | -51.87M | -4.4049 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-30 | 개시 | Evercore ISI | Outperform |
| 2024-12-05 | 개시 | Leerink Partners | Outperform |
| 2024-10-10 | 개시 | Oppenheimer | Outperform |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-12-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 개시 | William Blair | Outperform |
| 2023-08-28 | 개시 | H.C. Wainwright | Buy |
| 2023-07-03 | 개시 | BofA Securities | Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-01-27 | 개시 | Robert W. Baird | Outperform |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-22 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-04 | 개시 | Jefferies | Buy |
| 2021-05-04 | 개시 | Piper Sandler | Overweight |
| 2021-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Down 85.2% in March - MarketBeat
OnKure Therapeutics CFO Leverone sells $1.2k in shares - Investing.com UK
OnKure Therapeutics CFO Leverone sells $1.2k in shares By Investing.com - Investing.com Australia
OnKure Therapeutics CEO Saccomano sells $357 in stock By Investing.com - Investing.com Australia
OnKure Therapeutics CEO Saccomano sells $357 in stock - Investing.com
If You Invested $1,000 in OnKure Therapeutics (OKUR) - Stock Titan
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Published on: 2026-03-19 04:03:55 - baoquankhu1.vn
OnKure reports nearly $60M cash on hand as drug trials continue - BizWest
HC Wainwright Has Positive Forecast for OKUR Q1 Earnings - MarketBeat
OnKure Therapeutics (NASDAQ:OKUR) Price Target Lowered to $27.00 at HC Wainwright - Defense World
OnKure Therapeutics (OKUR): HC Wainwright & Co. Adjusts Price Ta - GuruFocus
H.C. Wainwright cuts OnKure stock price target to $27 on funding By Investing.com - Investing.com South Africa
H.C. Wainwright cuts OnKure stock price target to $27 on funding - Investing.com
Wall Street Zen Upgrades OnKure Therapeutics (NASDAQ:OKUR) to Hold - Defense World
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm
OnKure Therapeutics, Inc. 2025 Annual Report: Precision Oncology Pipeline and Focus on PI3Kα Inhibitors - Minichart
Onkure Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Breast cancer trial data and $59M cash: inside OnKure's 2026 pipeline plans - Stock Titan
OnKure Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Can OnKure Therapeutics Inc deliver consistent EPS growth2025 Market Trends & Accurate Intraday Trading Signals - baoquankhu1.vn
Onkure Therapeutics Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView
OKUR PE Ratio & Valuation, Is OKUR Overvalued - Intellectia AI
Pullback Watch: What is the PEG ratio of OnKure Therapeutics IncJuly 2025 Macro Moves & Weekly High Potential Stock Alerts - baoquankhu1.vn
Why OnKure Therapeutics Inc. stock appeals to dividend seekersWeekly Investment Recap & Expert Approved Trade Ideas - mfd.ru
[SCHEDULE 13G] OnKure Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 43.6% in January - Defense World
Is OnKure Therapeutics Inc. stock oversold or undervaluedJuly 2025 Rallies & Community Trade Idea Sharing Platform - mfd.ru
EV Market: Should I set a stop loss on OnKure Therapeutics Inc2025 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
Is OnKure Therapeutics Inc. in a bullish channelJuly 2025 Technicals & Technical Entry and Exit Tips - mfd.ru
Top Entero Therapeutics (GRDX) Competitors 2026 - MarketBeat
Published on: 2026-01-29 15:39:37 - mfd.ru
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), OnKure Therapeutics (OKUR) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Why OnKure Therapeutics Inc. stock could be next big winnerShort Interest Overview & High Yield Trading Alerts - bollywoodhelpline.com
Analyzing Nautilus Biotechnology (NASDAQ:NAUT) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Receives Average Rating of “Hold” from Analysts - Defense World
Published on: 2026-01-11 10:53:08 - Улправда
Targets Report: How risky is OnKure Therapeutics Inc stock nowEarnings Recap Summary & Weekly Sector Rotation Insights - Bộ Nội Vụ
How OnKure Therapeutics Inc. stock performs in weak economyEarnings Overview Report & Daily Market Momentum Tracking - Улправда
Geopolitics Watch: How risky is OnKure Therapeutics Inc. stock nowMarket Sentiment Review & Detailed Earnings Play Strategies - Улправда
Bear Alert: Will OnKure Therapeutics Inc stock attract ESG investorsFed Meeting & Weekly High Momentum Picks - Bộ Nội Vụ
Rally Mode: Why OnKure Therapeutics Inc. stock could be next big winnerJuly 2025 Snapshot & Safe Entry Trade Reports - Улправда
How OnKure Therapeutics Inc. stock performs after earnings - ulpravda.ru
What hedge fund activity signals for OnKure Therapeutics Inc. stock2026 world cup usa national team quarterfinals key players high defensive line odds analysis insights - ulpravda.ru
Will OnKure Therapeutics Inc. stock attract more institutional investors2026 world cup usa national team third place match playmakers high defensive line expert forecast expert opinion - ulpravda.ru
Quarterly Recap: How British Land Company PLC BLD stock expands through international marketsFed Meeting & AI Forecasted Entry and Exit Points - moha.gov.vn
Bull Bear: Why OnKure Therapeutics Inc stock is a must watch in 2025Weekly Profit Report & Low Risk Entry Point Tips - moha.gov.vn
OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Up 25.6% in December - Defense World
OnKure Therapeutics CEO Saccomano sells $258 in stock By Investing.com - Investing.com India
OnKure Therapeutics Inc Stock Analysis and ForecastDay Trading Setups & Identify Winning Stocks - earlytimes.in
Onkure Therapeutics Inc (OKUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):